This company has been acquired
JNCE Stock Overview
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. More details
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 0/6 |
| Financial Health | 6/6 |
| Dividends | 0/6 |
Community vs My Fair Value
Create NarrativeSelect a narrative for quick price alerts from the community, or create your own.
Jounce Therapeutics, Inc. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | US$1.88 |
| 52 Week High | US$5.49 |
| 52 Week Low | US$0.58 |
| Beta | 0.75 |
| 1 Month Change | -0.53% |
| 3 Month Change | 55.37% |
| 1 Year Change | -65.76% |
| 3 Year Change | -60.34% |
| 5 Year Change | -88.80% |
| Change since IPO | -89.10% |
Recent News & Updates
Recent updates
We're A Little Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Rate
Jan 04
Here's Why We're Watching Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation
Sep 20Here's Why We're A Bit Worried About Jounce Therapeutics' (NASDAQ:JNCE) Cash Burn Situation
Jun 16We Think Jounce Therapeutics (NASDAQ:JNCE) Can Easily Afford To Drive Business Growth
Feb 23Jounce Therapeutics: A Favorable Risk-Reward Ahead Of Critical 2022 Catalysts
Dec 16News Flash: Analysts Just Made A Dazzling Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) Forecasts
Aug 07Jounce Therapeutics: An Under The Radar And Undervalued Biotech
Jul 13Need To Know: Analysts Are Much More Bullish On Jounce Therapeutics, Inc. (NASDAQ:JNCE) Revenues
Jun 16Shareholders May Not Be So Generous With Jounce Therapeutics, Inc.'s (NASDAQ:JNCE) CEO Compensation And Here's Why
Jun 12We're Hopeful That Jounce Therapeutics (NASDAQ:JNCE) Will Use Its Cash Wisely
May 03Jounce Therapeutics (NASDAQ:JNCE) Shareholders Have Enjoyed An Impressive 163% Share Price Gain
Mar 02News Flash: Analysts Just Made A Sizeable Upgrade To Their Jounce Therapeutics, Inc. (NASDAQ:JNCE) Forecasts
Mar 02Have Insiders Sold Jounce Therapeutics, Inc. (NASDAQ:JNCE) Shares Recently?
Jan 13
A Look At Jounce Therapeutics' (NASDAQ:JNCE) CEO Remuneration
Dec 15Shareholder Returns
| JNCE | US Biotechs | US Market | |
|---|---|---|---|
| 7D | -2.6% | 5.1% | -1.1% |
| 1Y | -65.8% | -14.9% | 9.1% |
Return vs Industry: JNCE underperformed the US Biotechs industry which returned 16.2% over the past year.
Return vs Market: JNCE underperformed the US Market which returned -1.4% over the past year.
Price Volatility
| JNCE volatility | |
|---|---|
| JNCE Average Weekly Movement | 15.4% |
| Biotechs Industry Average Movement | 12.0% |
| Market Average Movement | 8.1% |
| 10% most volatile stocks in US Market | 16.9% |
| 10% least volatile stocks in US Market | 4.1% |
Stable Share Price: JNCE's share price has been volatile over the past 3 months.
Volatility Over Time: JNCE's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of US stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2012 | 141 | n/a | jouncetx.com |
Jounce Therapeutics, Inc., a clinical-stage immunotherapy company, develops therapies for the treatment of cancer. It develops vopratelimab, a clinical-stage monoclonal antibody, which is in Phase II clinical trial that binds to and activates the Inducible T cell CO-Stimulator, a protein on the surface of T cells found in various solid tumors. The company is also developing JTX-8064, a monoclonal antibody that binds to leukocyte immunoglobulin like receptor B2, which is a cell surface receptor expressed on macrophages; and Pimivalimab, an anti-PD-1 antibody for combination therapy.
Jounce Therapeutics, Inc. Fundamentals Summary
| JNCE fundamental statistics | |
|---|---|
| Market cap | US$98.96m |
| Earnings (TTM) | -US$50.92m |
| Revenue (TTM) | US$82.00m |
Is JNCE overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| JNCE income statement (TTM) | |
|---|---|
| Revenue | US$82.00m |
| Cost of Revenue | US$54.80m |
| Gross Profit | US$27.20m |
| Other Expenses | US$78.12m |
| Earnings | -US$50.92m |
Last Reported Earnings
Dec 31, 2022
Next Earnings Date
n/a
| Earnings per share (EPS) | -0.97 |
| Gross Margin | 33.17% |
| Net Profit Margin | -62.10% |
| Debt/Equity Ratio | 0% |
How did JNCE perform over the long term?
See historical performance and comparisonCompany Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2023/05/06 23:25 |
| End of Day Share Price | 2023/05/03 00:00 |
| Earnings | 2022/12/31 |
| Annual Earnings | 2022/12/31 |
Data Sources
The data used in our company analysis is from S&P Global Market Intelligence LLC. The following data is used in our analysis model to generate this report. Data is normalised which can introduce a delay from the source being available.
| Package | Data | Timeframe | Example US Source * |
|---|---|---|---|
| Company Financials | 10 years |
| |
| Analyst Consensus Estimates | +3 years |
|
|
| Market Prices | 30 years |
| |
| Ownership | 10 years |
| |
| Management | 10 years |
| |
| Key Developments | 10 years |
|
* Example for US securities, for non-US equivalent regulatory forms and sources are used.
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more.
Analysis Model and Snowflake
Details of the analysis model used to generate this report is available on our Github page, we also have guides on how to use our reports and tutorials on Youtube.
Learn about the world class team who designed and built the Simply Wall St analysis model.
Industry and Sector Metrics
Our industry and section metrics are calculated every 6 hours by Simply Wall St, details of our process are available on Github.
Analyst Sources
Jounce Therapeutics, Inc. is covered by 10 analysts. of those analysts submitted the estimates of revenue or earnings used as inputs to our report. Analysts submissions are updated throughout the day.
| Analyst | Institution |
|---|---|
| Colleen Kusy | Baird |
| Swayampakula Ramakanth | H.C. Wainwright & Co. |
| Cory Kasimov | J.P. Morgan |